HE4 As Prognostic Marker In Endometrial Cancer

The 17th International European Society of Gynaecological Oncology (ESGO) meeting runs from September 11 through the 14th in Milan, Italy. One interesting topic to be presented is the use of HE4 as a prognostic market in endometrial cancer. The abstract for this presentation is pasted below. I will follow up with any information that is shared when the meeting ends. I assume that HE4 testing will render the CA-125 obsolete for detecting recurrence.

"The HE4 (human epididymis protein4) has been shown to have the potential to differentiate between benign endometrial disease and endometrial cancer. The data presented will provide evidence that the HE4 serum levels are an independent prognostic markers for endometrial cancer patients."